Omega-3 Fatty Acids (DHA/EPA) for Mild Cognitive Impairment (MCI)
BResearch suggests 66.7% of RCTs in MCI populations reported positive cognitive outcomes with omega-3 supplementation. DHA appears to be the most critical component for brain-specific cognitive support.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'braincited.com';
const params = 'ingredient\u003Domega\u002D3\u002Ddha\u002Depa\u0026condition\u003Dmild\u002Dcognitive\u002Dimpairment';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
The Bottom Line
Research suggests 66.7% of RCTs in MCI populations reported positive cognitive outcomes with omega-3 supplementation. DHA appears to be the most critical component for brain-specific cognitive support.
Key Study Findings
Systematic Review
n=3582
Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms.
Dose: None
vs: Placebo or control
Outcome: Cognitive function in AD and MCI patients
Effect: None
None
Population: AD and MCI patients aged 50-90 (31 clinical trials)
Randomized Controlled Trial
n=73
12 weeks
Single-blind
Comparing the Efficacy of Combined Intralesional Triamcinolone Acetonide With Topical Calcipotriol Versus Intralesional Triamcinolone Acetonide …
Dose: IL triamcinolone every 4 weeks + calcipotriol twice daily
vs: IL triamcinolone acetonide alone
Outcome: Hair density (regrowth scale)
Effect: None
0.018 (scalp subgroup at wk12)
Population: Patients with scalp and beard alopecia areata (179 patches)
Review
Effects of Dietary Interventions on Cognitive Outcomes.
Dose: None
vs: None
Outcome: Cognitive outcomes (memory, executive function)
Effect: None
None
Population: Aging adults with cognitive impairment (review)
Review
Nutrition, cognition and chronic kidney disease: A comprehensive review of interactions and interventions.
Dose: None
vs: None
Outcome: None
Effect: None
None
Population: None
Other
Milk Fat Globules: 2024 Updates.
Dose: None
vs: None
Outcome: Inflammatory markers
Effect: None
None
Population: None
Systematic Review
The Role of Omega-3 Fatty Acid Supplementation in Slowing Cognitive Decline Among Elderly Patients With …
Dose: None
vs: None
Outcome: Cognitive function
Effect: None
None
Population: Alzheimer's disease patients
Key Statistics
18
Studies
3200
Participants
↑
Positive
B
Grade
Referenced Papers
European journal of …
2025
8 citations
Nutrients
2025
6 citations
Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms.
Systematic Review
International journal of …
2025
2 citations
Journal of cutaneous …
2025
European journal of …
2024
16 citations
Lasers in medical …
2024
10 citations
Healthcare (Basel, Switzerland)
2024
9 citations
Newborn (Clarksville, Md.)
2024
9 citations
Cureus
2024
8 citations
Journal of cosmetic …
2024
1 citations
American family physician
2024
Current opinion in …
2023
58 citations
Nutrition reviews
2023
18 citations
Archives of dermatological …
2023
3 citations
Vitamin Supplementation and Dementia: A Systematic Review.
Systematic Review
Nutrients
2022
76 citations
Brain, behavior, and …
2022
64 citations
European journal of …
2022
63 citations
The American journal …
2022
18 citations
Journal of Ayub …
2022
4 citations
The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review.
Review
Journal of clinical …
2021
38 citations
Antioxidants (Basel, Switzerland)
2021
33 citations
Diet enriched in omega-3 fatty acids alleviates olfactory system deficits in APOE4 transgenic mice.
Other
The European journal …
2021
4 citations
The Senior care …
2021
2 citations
Nutrients
2020
72 citations
Journal of cutaneous …
2020
21 citations
Psychiatrike = Psychiatriki
2020
15 citations
Journal of Alzheimer's …
2020
14 citations
FASEB journal : …
2020
8 citations
Omega-3 fatty acids and cognitive decline: a systematic review.
Systematic Review
Nutricion hospitalaria
2019
40 citations
Alzheimer's research & …
2019
29 citations
The journal of …
2018
24 citations
Journal of Alzheimer's …
2018
12 citations
FASEB journal : …
2017
41 citations
Actas espanolas de …
2017
22 citations
FASEB journal : …
2017
21 citations
Current Alzheimer research
2017
7 citations
Journal of Alzheimer's …
2016
128 citations
NeuroImage
2016
118 citations
FP essentials
2016
11 citations
Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis.
Meta-Analysis
Climacteric : the …
2015
92 citations
Journal of Alzheimer's …
2015
8 citations
European journal of …
2014
204 citations
Nutrition (Burbank, Los …
2014
74 citations
Acta clinica Belgica
2014
44 citations
Nutricion hospitalaria
2014
17 citations
Advances in nutrition …
2013
155 citations
Journal of Alzheimer's …
2012
257 citations
Journal of Alzheimer's …
2012
137 citations
Alzheimer disease and …
2011
52 citations
Molecular neurobiology
2010
145 citations
Journal of Alzheimer's …
2010
110 citations
Journal of Alzheimer's …
2010
55 citations
Women's health (London, …
2010
48 citations
JAMA
2009
304 citations
Progress in neuro-psychopharmacology …
2008
388 citations
Alternative medicine review …
2008
Alternative medicine review …
2007
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Commonly Used Dosages
- general:
- 1,000-2,000 mg combined DHA/EPA per day
- cognitivesupport:
- 1,000-1,700 mg/day (optimal dose-response curve)
Upper limit: 3,000 mg/day combined DHA/EPA (FDA GRAS)
Dosages Studied in Research
| Dosage | Duration | Effect | N |
|---|---|---|---|
| None | -- | Mixed | 3582 |
| IL triamcinolone every 4 weeks + calcipotriol twice daily | 12 weeks | Positive | 73 |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| Vitamin D3 vs triamcinolone acetonide | 12 weeks | Positive | 40 |
| None | -- | Positive | -- |
Best taken: With meals containing fat for better absorption
Safety & Side Effects
Reported Side Effects
- ⚠ Fishy aftertaste or burping
- ⚠ Mild gastrointestinal discomfort
- ⚠ Potential increased bleeding time at very high doses
- ⚠ May lower blood pressure slightly
Known Interactions
- ● Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (may reduce omega-3 absorption)
Tolerable upper intake: 3,000 mg/day combined DHA/EPA (FDA GRAS)
Always consult your healthcare provider before starting any supplement.
Frequently Asked Questions
Does Omega-3 Fatty Acids (DHA/EPA) help with Mild Cognitive Impairment (MCI)?
Based on 18 studies with 3,200 participants, there is moderate evidence from clinical studies that Omega-3 Fatty Acids (DHA/EPA) may support Mild Cognitive Impairment (MCI) management. Our evidence grade is B (Good Evidence).
How much Omega-3 Fatty Acids (DHA/EPA) should I take for Mild Cognitive Impairment (MCI)?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined DHA/EPA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (DHA/EPA)?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal discomfort, Potential increased bleeding time at very high doses, May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (DHA/EPA) and Mild Cognitive Impairment (MCI)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 18 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.
Related Evidence
Other ingredients for Mild Cognitive Impairment (MCI)
Omega-3 Fatty Acids (DHA/EPA) for other conditions
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.